NYSE · NVO
Novo Nordisk A/S
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NVO: Nov 04, 2026
Novo Nordisk A/S Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.81. The reported EPS for the same quarter last year was $1.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.81 | $0.86 | $0.75 | 4 |
| Dec 2026 | $0.70 | $0.78 | $0.54 | 3 |
| Mar 2027 | $0.91 | $0.95 | $0.87 | 2 |
| Jun 2027 | $0.92 | $0.93 | $0.91 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · Fintel · RTTNews- Zacks · Oct 30, 8:00 AM EDTHere is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending StockZacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- The Motley Fool · Oct 29, 4:36 PM EDTNovo Has Big Plans for 2030. Should You Buy the Stock Now?Novo plans to expand its lineup and pipeline by 2030, while serving far more patients.
- Zacks · Oct 29, 10:21 AM EDTLLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedLilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
- Zacks · Oct 27, 4:45 PM EDTNovo Nordisk (NVO) Stock Declines While Market Improves: Some Information for InvestorsIn the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.
- The Motley Fool · Oct 27, 11:10 AM EDTAmgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025.
- Zacks · Oct 27, 7:53 AM EDTBuy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsLilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
- Fintel · Oct 26, 12:50 PM EDTNovo Nordisk A/S Reports Share Repurchase Transactions Under DKK 15 billion ProgrammeNovo Nordisk A/S has announced transactions under its share repurchase programme. On 6 May 2026, the company initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission De
- Zacks · Oct 26, 9:02 AM EDTShould You Buy Viking Therapeutics Stock Ahead of Q3 Results?VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.
- Zacks · Oct 26, 8:30 AM EDTLLY vs. MRK: Which Stock Offers the More Compelling Investment Case?Lilly and Merck boast blockbuster drugs, expanding pipelines and new growth opportunities but pricing pressure, patent risks & competition shape their outlooks.
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- Zacks · Oct 22, 1:35 PM EDTRoche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesRoche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
- Zacks · Oct 22, 11:31 AM EDTNVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Novo Nordisk A/S from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.